Eribulin Monomethanesulfonate
Inflammatory Breast Carcinoma
Explore 25 assets in Inflammatory Breast Carcinoma →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05041101CT.gov Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Inflammatory Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Eribulin Monomethanesulfonate (this asset) | M.D. Anderson Cancer Center | P1/2 | CCC · 48 |
| Cyclophosphamide | Northwestern University | P3 | BBB |
| Trastuzumab | Hoffmann-La Roche | P3 | BBB |
| Carboplatin | Northwestern University | P3 | BBB |
| Docetaxel | Association Tunisienne de lutte Contre le Cancer | P3 | BBB |
| Pertuzumab | Hoffmann-La Roche | P3 | BBB |
| Epirubicin | Northwestern University | P3 | BB |
| Adriamycin | M.D. Anderson Cancer Center | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | RenJi Hospital | P3 | BB |
+41 more in the Inflammatory Breast Carcinoma cohort
Other indications for Eribulin Monomethanesulfonate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Neoplasm | — | P4 | BB · 69 |
| Breast Cancer | — | P4 | BB · 69 |
| Toxic Encephalopathy | — | P4 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Eribulin Monomethanesulfonate in Inflammatory Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/eribulin-monomethanesulfonate-inflammatory-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →